Joel E. Tepper, MD, on Radiotherapy in Liver and Pancreatic Cancers
2015 ASTRO Annual Meeting
Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline resectable and unresectable pancreatic tumors (Abstracts 253, 255, 351, 357).
Catherine C. Park, MD
Catherine C. Park, MD, of the University of California, San Francisco, summarizes results from three clinical trials of radiation therapy for various cancers: metastatic melanoma, oropharyngeal squamous cell carcinoma, and breast cancer (Abstracts 215, 3, and LBA7).
Supriya Chopra, MD
Supriya Chopra, MD, of Tata Memorial Hospital, discusses results of the PARCER study, which compared conventional 3D conformal radiotherapy to image-guided intensity-modulated radiotherapy in reducing bowel side effects for women with cervical cancer (Abstract 8).
Vratislav Strnad, MD, PhD
Vratislav Strnad, MD, PhD, of the University Hospital in Erlangen, discusses results from a European study comparing accelerated partial-breast irradiation using brachytherapy, to the standard treatment of whole-breast irradiation for women with low-risk breast cancer (Abstract LBA7).
Stephen G. Chun, MD
Stephen G. Chun, MD, of MD Anderson Cancer Center, discusses the comparison of 3D conformal and IMRT outcomes for locally advanced non-small cell lung cancer (Abstract 2).
Jay Harris, MD
Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal irradiation is beneficial.
